KW-2449

KW-2449 is an orally available, small molecule multi-targeted kinase inhibitor developed primarily for the treatment of hematologic malignancies. It potently inhibits FMS-like tyrosine kinase 3 (FLT3), including both wild-type and mutant forms, as well as ABL (including the T315I mutation), Aurora kinases, and to a lesser extent Fibroblast growth factor receptor 1. Its mechanism of action involves direct inhibition of these kinases, leading to disruption of downstream signaling pathways such as STAT5 phosphorylation in FLT3-mutant cells and histone H3 phosphorylation in wild-type FLT3 leukemia cells. This results in cell cycle arrest (G1 or G2/M phase) and apoptosis in susceptible cancer cells. Preclinical studies have shown significant antitumor activity against FLT3-mutated acute myeloid leukemia (AML) models with minimal bone marrow suppression. Clinical development has reached up to Phase 2 for AML and other hematologic neoplasms[1][2][4][6][7].